ArticleThe Eurasian journal of medicine2026
Small Interfering RNA Strategies to Overcome Drug Resistance in Cancer: Pathway Targeting and Translational Advances.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of therapeutic resistance remains the primary challenge to achieving durable responses in cancer treatment, thereby limiting the long-term e"cacy of several chemotherapies and targeted agents. Resistance may develop through diverse and often overlapping mechanisms. Conventional approaches to overcome resistance, such as dose escalation or combination regimens, are frequently constrained by systemic toxicity and adaptive tumor evolution. Moreover, many central drivers of resistance, including transcription factors and non-enzymatic regulatory proteins, remain inaccessible to therapeutics. Small interfering RNAs (siRNAs) o#er a fundamentally distinct and pathway-centric approach to overcoming drug resistance by enabling sequence-specific degradation of resistance-associated messenger RNAs. By acting upstream of protein synthesis, siRNA therapeutics can directly suppress both druggable and traditionally undruggable targets, including e$ux transporters, anti-apoptotic regulators, DNA repair enzymes, epigenetic modifiers, epithelial-mesenchymal transition transcription factors, and key oncogenic drivers such as KRAS and MYC. Advances in chemical modification and delivery platforms have significantly improved siRNA stability, specificity, and pharmacokinetic durability, enabling sustained gene silencing in vivo. The current review examines the molecular principles of siRNA-induced gene silencing and evaluates the current siRNA-based strategies targeting key mechanisms of chemotherapy resistance. Preclinical and translational studies demonstrating the reversal of multidrug resistance, restoration of apoptotic sensitivity, disruption of DNA repair-mediated tolerance, and suppression of adaptive oncogenic signaling are highlighted. In addition, the emerging clinical trials that validate siRNA-based approaches in cancer treatment are summerized. Cite this article as: Bardaweel SK, Hajjo R, Sabbah DA, Qasem DA. Small interfering RNA strategies to overcome drug resistance in cancer: pathway targeting and translational advances. Eurasian J Med. 2026, 58(1), 1350, doi:10.5152/eurasianjmed.2026.251350.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.